Huang ML, Shen GT, Li NL. Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment. World J Clin Cases 2022; 10(32): 11690-11701 [PMID: 36405275 DOI: 10.12998/wjcc.v10.i32.11690]
Corresponding Author of This Article
Nan-Lin Li, PhD, Professor, Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, No. 127 Changle West Road, Xi’an 710032, Shaanxi Province, China. linanlingo@126.com
Research Domain of This Article
Biochemistry & Molecular Biology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 16, 2022; 10(32): 11690-11701 Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11690
Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment
Mei-Ling Huang, Guang-Tai Shen, Nan-Lin Li
Mei-Ling Huang, Nan-Lin Li, Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an 710032, Shaanxi Province, China
Guang-Tai Shen, Department of Breast Surgery, Xing'an League People's Hospital, Ulanhot 137400, Inner Mongolia Autonomous Region, China
Author contributions: Shen GT and Li NL designed the research study and guide the writing; Huang ML performed the research, analyzed the data and wrote the manuscript; Shen GT guide the revision of the manuscript; all authors have read and approve the final manuscript. Huang ML and Shen GT contributed equally to this work.
Supported bythe National Natural Science Foundation of China, No. 81472598; and Project of Xijing Hospital, No. XJZT18MJ30.
Conflict-of-interest statement: All the authors declare that they do not have any conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nan-Lin Li, PhD, Professor, Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, No. 127 Changle West Road, Xi’an 710032, Shaanxi Province, China. linanlingo@126.com
Received: June 30, 2022 Peer-review started: June 30, 2022 First decision: August 21, 2022 Revised: August 30, 2022 Accepted: October 17, 2022 Article in press: October 17, 2022 Published online: November 16, 2022 Processing time: 131 Days and 5 Hours
Abstract
Breast cancer is the most frequently diagnosed cancer in women, accounting for 30% of new diagnosing female cancers. Emerging evidence suggests that ubiquitin and ubiquitination played a role in a number of breast cancer etiology and progression processes. As the primary deubiquitinases in the family, ubiquitin-specific peptidases (USPs) are thought to represent potential therapeutic targets. The role of ubiquitin and ubiquitination in breast cancer, as well as the classification and involvement of USPs are discussed in this review, such as USP1, USP4, USP7, USP9X, USP14, USP18, USP20, USP22, USP25, USP37, and USP39. The reported USPs inhibitors investigated in breast cancer were also summarized, along with the signaling pathways involved in the investigation and its study phase. Despite no USP inhibitor has yet been approved for clinical use, the biological efficacy indicated their potential in breast cancer treatment. With the improvements in phenotypic discovery, we will know more about USPs and USPs inhibitors, developing more potent and selective clinical candidates for breast cancer.
Core Tip: Ubiquitin-specific proteases (USPs) are emerging as potential therapeutic targets in many diseases. In breast cancer, several USPs were overexpressed. In this study, we summarize the involvement of USPs in breast cancer and the development of USP inhibitors, providing more reference to discover potent and selective clinical candidates.
